The UK's Medicines and Healthcare products Regulatory Agency has suspended the licence for lumiracoxib (Prexige) according to a press release.
Earlier this year restrictions were introduced following safety concerns about possible liver damage. A review of the most recent worldwide data has shown that liver reactions have occurred in patients taking low doses and for short periods.
Patients who are taking lumiracoxib and who feel well may continue with treatment but are advised to book a non urgent appointment to discuss alternative treatments. Patients taking the drug who feel unwell (particularly nausea, vomiting, loss of appetite, tiredness, stomach pains, dark urine, or itching or yellowing of the skin [jaundice]) are advised to stop treatment immediately.
hat tip: Matt
PS - it's also been pulled in Germany and Austria as well.
More
No comments:
Post a Comment